Ascendis Pharma Details Early Q2 YUVIWEL Launch Plan, Pricing Tease at TD Cowen Conference

Key Points

• Early Q2 launch for YUVIWEL is planned but hinges on final FDA packaging details; Ascendis says remaining steps are practical execution items and can begin commercial efforts ahead of first shipments while leveraging its existing SKYTROFA rare endocrine commercial infrastructure.
• Ascendis sees a meaningful U.S. opportunity—about 2,600 patients with less than one-third currently treated—and expects uptake from both switches (FDA labeling allows next-day transition from daily therapy) and previously untreated patients drawn by data showing benefits beyond linear growth, such as improved leg alignment and reduced surgical need.
• Pricing is expected soon; the company historically targets premium pricing tied to perceived superior benefits but says it will pursue a "fair" approach and rely on patient-support programs and medical-exception pathways rather than heavy payer contracting to enable access.

Ascendis Pharma A/S NASDAQ: ASND discussed plans to launch its newly approved achondroplasia therapy YUVIWEL during a virtual fireside chat at the 46th annual TD Cowen Healthcare Conference, held shortly after the company’s U.S. approval announcement.

YUVIWEL launch timing and readiness

Management said the planned early Q2 launch timeline is largely tied to final packaging-related details from the FDA, including final primary and secondary packaging and elements related to the product’s “inlet.” Once those details are received, the company said it needs to finalize printing and complete remaining preparations to ship product commercially. The company characterized the remaining steps as practical execution items rather than major barriers, noting that commercial efforts can begin ahead of first deliveries.

Ascendis also emphasized it intends to leverage an existing U.S. rare endocrine commercial infrastructure. The company described an established setup built around SKYTROFA and its rare endocrine portfolio, noting that more than 10,000 U.S. patients have been treated through its SKYTROFA program. Management said it expects to use the same structure for YUVIWEL, including overlap among prescribers.

Market opportunity and expected patient sources

During the discussion, the moderator cited estimates of about 2,600 U.S. patients and roughly 30% currently on drug, alongside the observation that a relatively small number of providers treat a majority of patients. In response, Ascendis said it believes less than one-third of U.S. achondroplasia patients are currently on treatment, implying a majority remain untreated.

Management said it expects YUVIWEL uptake to come from two groups:

• Switches from existing daily therapy: The company said it was pleased the FDA labeling provides clear instructions for switching—stop the daily therapy and start YUVIWEL the next day.
• Previously untreated patients: Ascendis argued that controlled data showing benefits beyond linear growth could bring more patients into therapy, particularly those focused on comorbidities rather than height.

The company highlighted outcomes it said extend beyond linear growth, including improvements related to leg bowing and leg alignment, and it described these benefits as potentially helping patients avoid surgeries and associated pain and disruption. It also referenced additional benefits such as muscle strength. Management added that combining therapy with calcitriol led to an acceleration of benefit, as described during the conversation.

Ascendis also suggested that different countries may have different “stories” driving treatment rates. It compared the U.S. to Italy, saying Italy has historically placed more emphasis on linear growth and has higher treatment penetration, and argued U.S. penetration could rise as comorbidity-focused evidence is communicated more broadly.

Label and safety discussion versus a daily CNP analog

The conversation addressed differences between YUVIWEL’s label and an existing therapy’s blood pressure-related warnings. Ascendis said the low blood pressure warning in YUVIWEL’s label references reports observed with a once-daily CNP analog, rather than an effect observed with YUVIWEL itself, framing it as a class-related precaution.

Management attributed YUVIWEL’s profile to its TransCon technology design goals, describing two key objectives:

• Sustained, one-week release intended to avoid high peak concentrations (Cmax) associated with hypotension risk.
• Prodrug design in which the active ingredient is initially inactive until released in the bloodstream, which management connected to reduced injection-site issues compared with daily injections.

Pricing and payer strategy comments

On pricing, the moderator said Ascendis indicated it expects to provide pricing information soon, potentially as early as the following week. Asked whether the company would pursue more payer contracting given competitive dynamics, management said it has historically priced products at a premium reflecting perceived superior benefits, while aiming for what it characterized as a “fair” approach that benefits patients and the broader system.

Ascendis indicated it is not heavily dependent on contracting, citing experience using medical exceptions and patient-support infrastructure to facilitate access. The company described an established “patient journey” approach intended to support access after prescriptions are written.

YORVIPATH update: demand, retention, and a weekly program

The discussion also touched on YORVIPATH, with questions about seasonality, gross-to-net dynamics, and early demand patterns. Ascendis said it expected to have more clarity by the end of March after seeing realized first-quarter numbers, while adding that demand has remained consistent quarter to quarter.

On persistence, management said that across countries, it generally sees patients remaining on YORVIPATH after starting therapy, with only a small percentage discontinuing. It said any drop-off tends to occur early, during titration, and the company is working to provide additional support during that phase.

Finally, Ascendis briefly addressed development of a once-weekly version of YORVIPATH, saying it is discussing with regulators whether a bioequivalence strategy based on pharmacokinetics could support approval or whether additional efficacy data would be required. The company emphasized that a weekly option would not be positioned as general life-cycle management, but rather as a conversion option for patients who have already been titrated to a stable dose on the daily product.

About Ascendis Pharma A/S NASDAQ: ASND

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company's lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.